Call Us 080-41656200 (Mon-Sat: 10AM-8PM)

Complement Regulatory Proteins in Breast Cancer


Marketed By :  LAP LAMBERT Academic Publishing   Sold By :  Kamal Books International  
Delivery in :  10-12 Business Days


Check Your Delivery Options

Rs. 5,886

Availability: In stock

  • Product Description

Choosing appropriate molecular markers is an intriguing area of oncology research to find out individualized treatments. Targeted therapy, which consists of therapeutic agents directed at specific molecules, is contemporary approach against cancers. This book looks at the impact of immune-editing on the aetiology of breast cancer to determine if this would provide novel prognostic markers for patients'' management. The expression of membrane CRPs (mCRP) CD59, CD55, CD46, also HLA class-I was measured on an extensive series of breast cancer tissues, using tissue microarrays. Tissue microarrays linked to good clinicopathological databases with a long term follow up are useful tools to determine new prognostic indicators that can be used in future clinical management. Both CD59 and HLA class-I were identified to be independent markers of prognosis. They could be used in addition to Nottingham Prognostic Index to help further stratify patients for adjuvant therapy. Patients lacking CD59 but expressing HLA could be candidates for aggressive chemotherapy as they have a poor predicted outcome.

Product Specifications
SKU :COC37412
AuthorZahra Madjd and Lindy Durrant
Number of Pages248
Publishing Year2010-11-01T00:00:00.000
Edition1 st
Book TypeClinical & internal medicine
Country of ManufactureIndia
Product BrandLAP LAMBERT Academic Publishing
Product Packaging InfoBox
In The Box1 Piece
Product First Available On ClickOnCare.com2015-07-31 00:00:00
0 Review(s)